

Regd. Office :

'Zydus Tower',
Satellite Cross Roads,
Ahmedabad 380 015. India.
Phone : +91-79-2686 8100 (20 Lines)
Fax : +91-79-2686 2368
www.zyduscadila.com

May 16, 2014

Bombay stock Exchange Limited
1st Floor, P.J. Towers
Dalal Street
MUMBAI – 400 001

Kind Attn.: Mr. Kapoor
Mr. Goopalkrishnan

National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor
Plot No. C/1, G Block
Bandra-Kurla Complex
Bandra – (East)
Mumbai – 400 051

Kind Attn.: Famroze Pochara
Asst. Vice President

Ahmedabad Stock Exchange Limited
Kamdhenu Complex
Opp. Sahajanand College
Panjara Pole,
Ahmedabad – 380 015

Dear Sir


Re.: Press Release

We are forwarding you herewith copy of press release proposed to be published in the newspapers in the matter of audited financial results for the year ended on March 31, 2014 the same may please receive in order.

Thanking you

Yours faithfully

For **CADILA HEALTHCARE LIMITED**



UPEN H. SHAH
COMPANY SECRETARY

Encl.: As above

Zydus Cadila's Net Profit zooms to Rs. 804 crore

Ahmedabad, May 16, 2014

Zydus Cadila posted excellent results for the year ended 31st March 2014 and registered a Net Profit of Rs. 804 crores, up by 23% from Rs. 654 crores. During the year, the company registered gross sales of Rs. 7208 crores, up by 15% from Rs. 6285 crores in the last year, on a consolidated basis.

For the fourth quarter ended 31st March 2014, the group registered gross sales of Rs. 1952 crores, up by 22% from Rs. 1599 crores in the corresponding period last year on a consolidated basis. Net Profit for the same period stood at Rs. 239 crores. The Board of Directors of the Company in their meeting proposed a dividend of 180%.

The topline growth was mainly driven by 30% growth in formulation exports, which was buoyed by 44% growth in sales in the US market and 17% growth in the emerging markets. In the US, the group which is ranked amongst the 8th largest generic companies, launched 7 new products. The group also launched operations in Mexico with launch of 7 products during the year.

The group's India formulations business launched more than 75 new products including line extensions, of which 19 were 1st in India. This was a milestone year for the group as it marked the launch of Lipaglyn, the breakthrough therapy to treat diabetic dyslipidemia and India's first NCE to reach the market.

With a continued thrust on its discovery research programme, the group announced the commencement of Phase I clinical trials for ZYDPLA1 - a Next Generation, long-acting DPP-4 Inhibitor. Currently, all available DPP-4 inhibitors are dosed once-daily. ZYDPLA1 with a once-a-week dosing regimen, would provide diabetic patients with a more convenient treatment alternative. ZYDPLA1 will offer sustained action, which will result in an improved efficacy profile.

Strengthening its regulatory pipeline, the group filed a record 50 ANDAs during the year with the US FDA, taking the cumulative filings to 227. The group received 15 ANDA approvals during the year taking the total to 91 product approvals.